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Abstract The protein chaperone heat shock protein 90 (Hsp90)
is a major regulator of different transcription factors such as
MyoD, a basic helix loop helix (bHLH) protein, and the bHLH-
Per-aryl hydrocarbon nuclear translocator (ARNT)-Sim (PAS)
factors Sim and aryl hydrocarbon receptor (Ahr). The transcrip-
tion factor hypoxia-inducible factor-1K (HIF-1K), involved in the
response to hypoxia, also belongs to the bHLH-PAS family.
This work was aimed to investigate the putative role of Hsp90 in
HIF-1 activation by hypoxia. Using a EGFP-HIF-1K fusion
protein, co-immunoprecipitation experiments evidenced that the
chimeric protein expressed in COS-7 cells interacts with Hsp90
in normoxia but not in hypoxia. We also demonstrated that
Hsp90 interacts with the bHLH-PAS domain of HIF-1K.
Moreover, Hsp90 is not co-translocated with HIF-1K into the
nucleus. At last, we showed that Hsp90 activity is essential for
HIF-1 activation in hypoxia since it is inhibited in the presence of
geldanamycin. These results indicate that Hsp90 is a major
regulator in HIF-1K activation.
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1. Introduction
In response to a reduced oxygen level, activation of hy-
poxia-inducible factor-1 (HIF-1) regulates the transcription
of several genes such as erythropoietin, vascular endothelial
growth factor, inducible nitric oxide synthase, T [1]. All these
genes are involved in the adaptative response of the cell and
tissue to the hypoxic conditions. HIF-1 is a heterodimeric
complex composed of two subunits belonging to the Per-
aryl hydrocarbon nuclear translocator (ARNT)-Sim (PAS)-
basic helix loop helix (bHLH) family, HIF-1K and ARNT
[2,3]. The mechanism of hypoxia-dependent function and ac-
tivation of the HIF-1K-ARNT complex is currently poorly
understood. The HIF-1K protein level is speci¢cally upregu-
lated under hypoxic conditions, through a redox-dependent
proteolytic stabilization to prevent HIF-1K rapid degradation
by the proteasome pathway [4,5]. HIF-1K then translocates
into the nucleus where it dimerizes with ARNT [6] to form
the active complex HIF-1.
ARNT is a common factor already known as Ah receptor
nuclear translocator [7], which functions in association with
Ah receptor as an activator of the transcriptional response of
cells to dioxin and other xenobiotics [7]. In the absence of
ligand, aryl hydrocarbon receptor (Ahr) exists in an inducible
cytoplasmic form associated with the chaperone protein heat
shock protein 90 (Hsp90) [8]. Upon ligand binding, Hsp90
dissociates concomitantly, unmasking the dimerization and
DNA binding activities of Ahr [9]. Hsp90 chaperone is among
the most abundant proteins in the cytosol of eukaryotic cells
[10,11]. As chaperone, Hsp90 prevents the aggregation of un-
folded proteins generated by heat shock [12], oxidative [13] or
ischemic stresses [14]. In addition, Hsp90 is a major partner of
di¡erent transcription factors. Among these factors are zinc
¢nger proteins such as glucocorticoid receptor [15], bHLH
proteins such as MyoD [16] and bHLH-PAS proteins such
as Sim and Ahr [6].
Although HIF-1K activity does not seem to be upregulated
by ligand binding such as Ahr, there are striking similarities in
functional properties between these two factors. Most notably
is the dimerization with the common subunit ARNT. In ad-
dition, Gradin et al. demonstrated that HIF-1K is able to bind
Hsp90 in vitro [17], but it is not known whether Hsp90 mod-
ulates HIF-1K activity as it does for Ahr.
This work was aimed to elucidate the role of this chaperone
in the regulation of HIF-1K translocation and of HIF-1 tran-
scriptional activity. We observed that Hsp90 is associated with
HIF-1K in normoxia and is necessary to obtain an activable
form of HIF-1 by hypoxia in COS-7 and human microvascu-
lar endothelial (HMEC-1) cells.
2. Materials and methods
2.1. Cell culture
HMEC-1 [19] were grown in MCDB 131 (Gibco, Paisley, UK)
containing 15% fetal calf serum and 10 ng/ml EGF, 1 Wg/ml hydro-
cortisone, 10 mM glutamine, 50 U/ml penicillin G, 50 ng/ml ampho-
tericin B. COS-7 cells were grown in DMEM (Gibco, Paisley, UK)
containing 10% fetal calf serum, 50 U/ml penicillin G, 50 ng/ml am-
photericin B and 20 mM HEPES (pH 7.4). Chemical hypoxia were
performed in the presence of 150 WM CoCl2 [20]. Normoxia and
hypoxia incubations were performed in CO2-independent medium
(Gibco, Paisley, UK) supplemented with 2% fetal calf serum, 10
mM glutamine, 50 U/ml penicillin G, 50 ng/ml amphotericin B (Gib-
co) with respectively 21 and 1% O2.
2.2. Transient transfection and reporter gene assays
To assay the activity of HIF-1, we used the pGL-3SV40HRE vector
which contains three copies of the EPO hypoxia responsive element
(HRE) downstream from the luciferase gene [21], for which the ex-
pression is driven by a heterologous SV40 promoter. HMEC-1/COS-7
transfection was performed in a 96 well plate at 80^90% con£uency
with DOTAP transfection reagent (Boehringer Mannheim), 600 ng of
PGL-SV40. This vector was co-transfected with 200 ng of the control
vector pRL-SV40 (Promega, Madison, WI, USA). Twenty-four hours
post-transfection, luciferase activity is measured. Luciferase activity
was quantitated in a luminometer using the Dual-Luciferase-Reporter
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System (Promega, Madison, WI, USA). The EGFP-HIF-1K and
EGFP-CHIF-1K fusion proteins were obtained by cloning respectively
the complete HIF-1K coding sequence (2480 bp) and the sequence
between position 1578 and 2480 in the pEGFP-C1 (Clontech, Palo
Alto, CA, USA). The resulting plasmids were called pEGFP-HIF-1K
and pEGFP-CHIF-1K. The EGFP-HIF-1K and EGFP-CHIF-1K fu-
sion proteins were transiently expressed in COS-7 cells grown in 25
cm2 £asks for immunoprecipitation experiments and on glass cover-
slips placed in a six well plate for immuno£uorescence experiments.
The cells were transfected with DOTAP and 2.5 Wg of plasmid. The
cells were incubated during 4 h with the transfection solution. Then,
the cell medium was replaced with fresh DMEM containing 10%
serum.
2.3. Immunoprecipitation and Western blot analysis
Total cell extracts were prepared from COS-7 cells grown in 25 cm2
£asks and transfected with the pEGFP-HIF-1K, pEGFP-CHIF-1K or
pEGFP. Twenty-four hours post-transfection, the cells were incubated
for 2 h and 30 min in normoxia or in hypoxia. Then, the cells were
washed with ice-cold phosphate-bu¡ered saline (PBS) and lysed using
the extraction bu¡er (Tris 40 mM pH 7.5, KCl 300 mM, EDTA
2 mM, Triton X-100 1%, protease and phosphatase inhibitors). The
lysate was collected in micro-centrifuge tubes and incubated on ice for
30 min. The lysate was centrifugated 15 min at 15 000 rpm, 4‡C, and
the supernatant was collected. An aliquot of 50 Wl of this supernatant
was boiled and kept frozen (supernatant 1). Hsp90 antibodies (H9010
antibodies provided by Prof. D. Toft, Department of Biochemistry
and Molecular Biology, Mayo Clinic, Rochester, MN, USA) and
40 Wl of Sepharose-protA beads (Pharmacia, Uppsala, Sweden) were
added and incubated with the supernatant overnight at 4‡C. Then, the
beads were collected with the Hsp90 antibodies and the interacting
complex by centrifugation for 5 min at 15 000 rpm, 4‡C. The super-
natant was boiled and kept frozen (supernatant 2). The pellet was
washed three times with 800 Wl of cold extraction bu¡er and collected
by centrifugation for 5 min at 15 000 rpm, 4‡C. At last, 40 Wl of
loading bu¡er was added to the beads and the mix was boiled before
being frozen. The di¡erent extracts (supernatant 1, 2 and immunopre-
cipitated fraction) were resolved on 10% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) gels and then transferred
to a PVDF membrane. After blocking in phosphate saline bu¡er
containing 0.2% Tween and 5% dried milk, the blot was probed
with mouse anti-EGFP antibodies (Clontech, Palo Alto, CA, USA)
or with mouse anti-Hsp90 antibodies (both at 1/2500 dilution). Anti-
mouse horseradish peroxidase-conjugated secondary antibodies
(Amersham Pharmacia, Uppsala, Sweden) were used for detection
by chemiluminescence.
2.4. In vitro transcription-translation
The bHLH-PAS domain (amino acid positions 1^330) [18] coding
sequence of HIF-1K was cloned into the pET-3a expression vector
(Novagen, Madison, WI, USA). Two Wg of this new plasmid was
incubated with wheat germ extract, [35S]methionine and T7 polymer-
ase according to the procedure described in the TNT (Promega, Mad-
ison, WI, USA) protocol. In order to know whether the bHLH-PAS
domain of HIF-1K interacts with Hsp90, the radiolabelled transcrip-
tion-translation product was incubated for 4 h with total extracts of
COS-7 cells. These samples were prepared using the extraction bu¡er
described in Section 2.3. Hsp90 antibodies were added with Sephar-
ose-protA beads and the mix was incubated overnight. The super-
natant was then discarded and the beads and the interacting proteins
were washed ¢ve times as described in the immunoprecipitation pro-
cedure. The extracts were loaded on a 14% SDS-PAGE gel. Then, the
gel was dried and the immunoprecipitated product was detected by
autoradiography.
2.5. Northern blot analysis
Total RNA was isolated from hypoxic and normoxic COS-7 cells
by the guanidium thiocyanate method. Three Wg of total RNA from
each sample of COS-7 cells was loaded on a 1.5% agarose formalde-
hyde gel and transferred to a Hybond-N nylon membrane (Amer-
sham). The probe used is 207 bp long and hybridizes on the third
exon of the human Hsp90. As internal control, an ubiquitin probe
was used (Clontech, Palo Alto, CA, USA). Both probes were labelled
by random priming (Amersham Pharmacia, Uppsala, Sweden) using
[Q-32P]dCTP. Hybridization was performed at 42‡C in a 50% forma-
mide medium.
2.6. Immuno£uorescence
COS-7 cells grown on glass coverslip were transiently transfected
with the pEGFP-HIF-1K or the pEGFP-CHIF-1K vectors. Twenty-
four hours post-transfection, the medium was replaced by fresh CO2-
independent medium and the cells were incubated for 2 h and 30 min
in normoxia or in hypoxia. Then, the cells were washed with PBS and
¢xed 10 min with PBS containing 4% paraformaldehyde. The ¢xed
cells were washed three times with PBS and permeabilized with a
solution of PBS+Triton X-100 1%. After three washing steps with
PBS+BSA 3%, the cells were incubated for 2 h with the anti-Hsp90
antibodies in PBS+BSA 3%. Then, the cells were washed three times
with PBS+BSA 3% and the secondary anti-mouse TRITC-conjugated
antibodies were added to the cells. After 1 h of incubation, the cells
were washed three times with PBS+BSA before ¢xation in mowiol.
Observations were performed using a confocal microscope (Leica,
Hamburg, Germany).
Fig. 1. Hsp 90-dependent activation of HIF-1. (A) Schematic repre-
sentation of the reporter plasmids used. The pGL-3SV40 is a lucif-
erase reporter plasmid, the Luc gene expression is dependent on a
heterologous SV40 promoter. The pGL-3SV40HRE reporter con-
struct expresses a luciferase reporter gene under the dependence of
both the SV40 promoter and three HREs. HMEC-1 cells (B) and
COS-7 cells (C) were co-transfected either with the pGL-3SV40 or
pGL-3SV40HRE together with the pRL-SV40 control vector. Five
hours after transfection, the cells were incubated for 20 h either in
the absence or in the presence of 150 WM CoCl2 inducing a chemi-
cal hypoxia. Then, the cells were lysed for luciferase assays. Data
represent the ratio between test ¢re£y luciferase activity and renilla
luciferase activity (RF/R). Results are presented as means þ S.D. for
triplicates.
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3. Results
3.1. Hsp90 is necessary for HIF-1 activity
Several works were aimed to understand the role of Hsp90
in the regulation of transcription factor activity (glucocorti-
coid receptor, Ahr). The glucocorticoid receptor is activated
in the presence of dexamethasone, but this activation is inhib-
ited when cells are treated with geldanamycin, a Hsp90 spe-
ci¢c inhibitor [22,23]. In yeast expressing a regulatable level of
Hsp90, the Ahr signaling pathway is disrupted when the ex-
pression of Hsp90 falls to 5% of its normal level [24]. All these
data suggest that Hsp90 is a major component in the regula-
tion of the activity of transcription factors such as steroid
receptors and bHLH-PAS factors [22,25]. In order to inves-
tigate whether Hsp90 is involved in HIF-1 activation under
hypoxic conditions, we used a luciferase reporter system pGL-
3SV40HRE (Fig. 1A) where the Luc gene expression is regu-
lated by three HREs [21]. It has previously been shown that
the luciferase activity is a¡ected by Hsp90 only in vitro [10].
The reporter system was transfected into endothelial cells
(HMEC-1) and into COS-7 cells. The cells were then incu-
bated during 24 h in the absence or in the presence of 150
WM CoCl2, a HIF-1 activator [20], with or without geldana-
mycin. This chemical hypoxia was able to increase the lucifer-
ase activity by 4-fold in HMEC-1 (Fig. 1B) and by 2-fold in
COS-7 cells (Fig. 1C). Interestingly, a very strong inhibition of
HIF-1 activation was observed in both CoCl2-treated HMEC-
1 (Fig. 1B) and COS-7 (Fig. 1C) cells in the presence of
geldanamycin. No inhibition of luciferase expression was de-
tected in normoxic cells treated with geldanamycin and trans-
fected with the pGL-3SV40HRE. The luciferase expression
remained constant under the di¡erent conditions in cells
transfected with the pGL-3SV40 control plasmid (Fig.
1B,C). These results suggest that Hsp90 activity is needed
for the hypoxia-induced activation of HIF-1.
3.2. HIF-1K is associated with Hsp90 in normoxia
ARNT is a nuclear factor that does not interact with Hsp90
[26], so that we hypothesized that Hsp90 interacts with HIF-
1K. In order to con¢rm the interaction between HIF-1K and
Hsp90, we used the chimeric EGFP-HIF-1K and EGFP-
CHIF-1K proteins which are respectively fusion proteins be-
tween EGFP and the complete HIF-1K sequence and between
EGFP and the carboxy-terminal domain of HIF-1K. The fu-
sion between the EGFP and HIF-1K or its carboxy-terminal
domain produces a more stable protein than HIF-1K alone
[18], which is degraded in normoxia [4]. This system allowed
us to overexpress HIF-1K chimeric proteins in COS-7 cells.
COS-7 cells were transfected with plasmids encoding EGFP,
EGFP-HIF-1K or EGFP-CHIF-1K (Fig. 2A). Twenty-four
hours later, the cells were incubated in normoxia or in hy-
poxia for 2 h and 30 min. The cells were then lysed and
incubated in the presence of Hsp90 antibodies in order to
co-immunoprecipitate Hsp90 and Hsp90-interacting proteins.
The co-immunoprecipitated proteins were resolved on a poly-
acrylamide gel and the EGFP chimeric proteins were detected
by Western blotting using anti-EGFP antibodies. As shown in
Fig. 2B, EGFP-HIF-1K was co-immunoprecipitated with
Hsp90 in normoxia. In hypoxia, a very small amount of
EGFP-HIF-1K interacting with Hsp90 was detected (Fig.
2B). EGFP alone did not interact with Hsp90 (not shown).
No EGFP-CHIF-1K proteins were immunoprecipitated nor in
normoxia neither in hypoxia (not shown). A Western blotting
analysis using Hsp90 antibodies was performed on the same
blot, showing that a similar amount of Hsp90 was immuno-
precipitated in each sample (Fig. 2C). Interestingly, the
EGFP-CHIF-1K was recovered into the supernatant of immu-
noprecipitation (Fig. 2D). These results indicate that HIF-1K
interacts with Hsp90 in normoxia and that the interacting
domain is not within the 300 last amino acids.
3.3. Hsp90 interacts with the bHLH-PAS domain of HIF-1K in
vitro
It has been shown that Hsp90 is able to interact with two
di¡erent domains of Ahr, the ¢rst being in the bHLH domain
[9] and the second in the PAS B domain [9]. Results from Fig.
Fig. 2. EGFP-HIF-1K chimeric protein but not EGFP-CHIF-1K
protein is co-immunoprecipitated with Hsp90. (A) Schematic repre-
sentation of the chimeric proteins. (B) COS-7 cells were transfected
with the pEGFP-HIF-1K or pEGFP-CHIF-1K. Twenty-four hours
post-transfection, the cells were incubated in either hypoxia (1% O2)
or normoxia (21% O2) and the total protein extracts were prepared.
Co-immunoprecipitation was performed using Hsp90 speci¢c anti-
bodies. (a) Western blot analysis was performed using anti-EGFP
antibodies. (b) The amount of Hsp90 immunoprecipitated in each
sample was checked by Western blot using antibodies against
Hsp90. (c) Western blot analysis performed on the co-immunopre-
cipitation supernatant using anti-EGFP antibodies.
Fig. 3. The bHLH-PAS domain of HIF-1K is co-immunoprecipi-
tated with Hsp90. (A) Schematic representation of the HIF-1K
bHLH-PAS domain. (B) The in vitro transcription-translation prod-
uct (lane 3) was incubated with COS-7 cell protein extracts. Sephar-
ose-protA beads alone (lane 1) or Sepharose-protA beads+Hsp90
antibodies (lane 2) were added to the samples and incubated over-
night. After ¢ve washing steps, the co-immunoprecipitated proteins
were resolved on a SDS-PAGE gel and detected by autoradiogra-
phy.
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2 indicate that HIF-1K interacts with Hsp90 and that this
interaction does not involve the carboxy-terminal end of
HIF-1K. We then wanted to know whether Hsp90 interacts
with the bHLH-PAS domain of HIF-1K. The HIF-1K bHLH-
PAS domain [3] was cloned into the pET-3a expression vector.
In vitro transcription-translation was performed in wheat
germ lysate in order to produce radiolabelled HIF-1K
bHLH-PAS domain (Fig. 3A). It is important to notice that
in other experiments using this system, no binding of wheat
Hsp90 was obtained with the bHLH-PAS domain of Ahr,
avoiding false positive results [9]. Then, the radiolabelled
HIF-1K bHLH-PAS domain was incubated in the presence
of COS-7 cell extract and a co-immunoprecipitation experi-
ment using anti-Hsp90 antibodies was performed. As shown
in Fig. 3B, the bHLH-PAS domain of HIF-1K was co-immu-
noprecipitated by the anti-Hsp90 antibodies. When the anti-
Hsp90 is not added, the bHLH-PAS domain was not recov-
ered.
3.4. Hsp90 is not translocated into the nucleus with
EGFP-HIF-1K
One hypothesis concerning the nuclear translocation of the
bHLH-PAS factor Ahr is that the binding of one molecule of
dioxin onto the Ahr protein leads to its dissociation from
Hsp90 allowing for its translocation to the nucleus [27]. The
interacting element of Ahr with Hsp90 is the bHLH-PAS
domain [9]. In comparison, the oxygen-dependent mechanism
of activation of HIF-1K is not known. Indeed, there are no
data regarding a putative ligand for HIF-1K. This ligand does
not seem to be a heme but phosphorylation [28] has been
reported. Phosphorylation could provoke the dissociation of
HIF-1K and Hsp90 under hypoxic conditions. We have indeed
shown in Fig. 2 that the interaction of EGFP-HIF-1K and
Hsp90 is weaker in hypoxia. In order to investigate whether
Hsp90 is involved in HIF-1K translocation into the nucleus
during hypoxia, we performed immuno£uorescence experi-
ments. Hypoxic or normoxic COS-7 cells expressing EGFP-
HIF-1K or EGFP-CHIF-1K were ¢xed, permeabilized and
Fig. 4. Hsp90 is not co-translocated with EGFP-HIF-1K into the nucleus upon hypoxia. COS-7 cells were transfected with the pEGFP-HIF-1K
vector. Twenty-four hours post-transfection, the cells were incubated in either normoxia (21% O2) or hypoxia (1% O2) for 2 h and 30 min.
After ¢xation and permeabilization, the cells were labelled with Hsp90 antibodies and TRITC anti-mouse-conjugated antibodies. The respective
cellular localization of Hsp90 and fusion proteins was detected in confocal microscopy. Localization of the EGFP-HIF-1K protein and of
Hsp90 in normoxia (A) and hypoxia (B). Magni¢cation: 1000U
Fig. 5. Hypoxic regulation of Hsp90 expression. COS-7 cells were
exposed to either normoxia (21% O2) or hypoxia (1% O2) during 2 h
and 30 min. (A) Western blot analysis of Hsp90 in normoxia (N)
and in hypoxia (H). (B) Northern blot analysis of Hsp90 (a) and
ubiquitin (b) mRNA in normoxia (N) and hypoxia (H).
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labelled with anti-Hsp90 antibodies detected by TRITC anti-
mouse Ig. Putative co-localization of Hsp90 and EGFP-HIF-
1K/EGFP-CHIF-1K was studied using confocal microscopy.
First, we detected an increase in cytosolic Hsp90 during hy-
poxia (Fig. 4A,B). This increase was con¢rmed by Northern
and Western blotting (Fig. 5A,B). As shown in Fig. 4A, in
normoxia, the EGFP-HIF-1K protein was present through the
whole cell and Hsp90 is mainly peri-nuclear but also in the
cytoplasm. In hypoxia (Fig. 4B), EGFP-HIF-1K was trans-
located into the nucleus, but this did not provoke any increase
in the Hsp90 present within the nucleus in comparison to non-
transfected cells. Regarding the EGFP-CHIF-1K (Fig. 6), this
chimeric protein was nuclear in normoxia (A) and in hypoxia
(B) as already shown by Kallio et al. [18]. These results in-
dicate that Hsp90 does not seem to translocate into the nu-
cleus with HIF-1K in hypoxia.
4. Discussion
Studies of interactions between Hsp90 and transcription
factors such as steroid hormone receptors [15], MyoD [16],
HSF1 [29], Sim and Ahr [6] allowed us to elucidate the role
of this chaperone molecule in the complex regulatory mecha-
nisms leading to the activation of these factors. The folding of
the bHLH and PAS domains of the dioxin receptor Ahr is
dependent on Hsp90 [9]. Moreover, its ability to bind its li-
gand [30], to dimerize with ARNT [30] and to bind DNA is
also Hsp90-dependent [30].
In this work, we investigated the role of Hsp90 in HIF-1
activation by hypoxia. However, the mechanism leading to its
activation upon hypoxia is far from being completely under-
stood. The results shown here evidence that geldanamycin
inhibits the activation of HIF-1 in hypoxia. Geldanamycin
is able to inhibit the ATP binding activity of Hsp90, leading
to the formation of a low a⁄nity Hsp90 complex for sub-
strates [15,31]. The fact that geldanamycin inhibited HIF-1
activation indicates that Hsp90 activity is needed for this ac-
tivation. Since it is known that ARNT does not interact with
Hsp90 [26], we sought whether HIF-1K is a partner for Hsp90.
By co-immunoprecipitation studies using anti-Hsp90 antibod-
ies and total extracts from cells expressing the stabilized
EGFP-HIF-1K and EGFP-CHIF-1K chimeric proteins, we
showed that EGFP-HIF-1K interacts with Hsp90 in normoxia
but to a much lesser extent in hypoxia. The truncated protein
EGFP-CHIF-1K expressing the C-terminal end of HIF-1K
and located within the nucleus does not interact with
Fig. 6. Hsp90 is not co-translocated with EGFP-CHIF-1K into the nucleus. COS-7 cells were transfected with the pEGFP-CHIF-1K vector.
Twenty-four hours post-transfection, the cells were incubated in either normoxia (21% O2) or hypoxia (1% O2) for 2 h and 30 min. After ¢xa-
tion and permeabilization, the cells were labelled with Hsp90 antibodies and TRITC anti-mouse-conjugated antibodies. The respective cellular
localization of Hsp90 and fusion proteins was detected in confocal microscopy. Localization of the EGFP-CHIF-1K protein and of Hsp90 in
normoxia (A) and hypoxia (B). Magni¢cation: 400U.
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Hsp90. These results indicate that HIF-1K actually interacts
with Hsp90 and that this interaction is not mediated by the C-
terminal domain of the protein. Moreover, HIF-1K seems to
dissociate from Hsp90 in hypoxia. Interestingly, both proc-
esses are similar to what is observed for Ahr [27]. First, in
Ahr-Hsp90 complex, Hsp90 proteins are bound to the bHLH-
PAS domain [9]. As the C-terminal end of HIF-1K did not
immunoprecipitate with Hsp90, we supposed that the interac-
tion between Hsp90 and HIF-1K is also located within the
bHLH-PAS domain. This hypothesis was con¢rmed by an
in vitro experiment showing that the HIF-1K bHLH-PAS do-
main was co-immunoprecipitated by anti-Hsp90 antibodies.
Secondly, with respect to Ahr, Hsp90 dissociates when the
ligand, dioxin, interacts with its receptor, enabling nucleus
translocation and dimerization with ARNT [27]. Results
from Fig. 2 suggest that Hsp90 is released from HIF-1K under
hypoxic conditions, i.e. when HIF-1K is activated by hypoxia,
the exact mechanism leading to this activation still being un-
clear. One can thus hypothesize that Hsp90 could play a sim-
ilar role for HIF-1K as for Ahr, holding HIF-1K in a re-
pressed state and/or chaperoning its folding and the
‘activable’ conformation of HIF-1K under normoxic condi-
tions [8,9,30].
Another interesting feature of Hsp90 is its putative role in
regulating nuclear translocation [23]. Results from Fig. 6 show
that the chimeric protein EGFP-CHIF-1K is constitutively
translocated into the nucleus. This translocation is due to
the presence of an unmasked RKRK motif in the C-terminal
domain of HIF-1K [18]. This was already observed by Kallio
et al. [18]. They suggested that either the complete HIF-1K
protein folds upon itself so that this NLS is masked in nor-
moxic conditions and that HIF-1K is located within the cyto-
sol or that Hsp90 interacting with HIF-1K could mask this
NLS. Using the EGFP-HIF-1K chimeric protein, we were not
able to detect by confocal microscopy any co-translocation
into the nucleus of Hsp90 with HIF-1K during hypoxia.
This result con¢rms that in hypoxia, the binding of Hsp90
to HIF-1K is unstable as observed in the co-immunoprecipi-
tation studies. However, the role of Hsp90 in the translocation
mechanism of HIF-1K into the nucleus upon hypoxia remains
unclear and it could be possible that nuclear Hsp90 will also
be involved in HIF-1K regulation as for Ahr [31].
It must be noted that an increase in the Hsp90 mRNA and
protein levels was observed under hypoxic conditions. This
increase could be due to cell injuries resulting from hypoxia
[32]. Other Hsps have already been shown to be induced by
ischemic conditions [14].
In conclusion, we showed that HIF-1K interacts with Hsp90
in vivo in normoxia and that the interaction involves the
bHLH-PAS domain of HIF-1K, as for Ahr. In addition, the
presence of an active Hsp90 is necessary for HIF-1 activation
in hypoxia. However, there is no evidence for the involvement
of Hsp90 in the translocation of HIF-1K. In the future, it will
be interesting to investigate precisely the levels at which the
chaperone is acting: folding, regulation of proteasomal deg-
radation and/or nuclear import regulation.
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